The pharmaceutical industry often complains that the "media" are unfriendly and biased against the industry. And at least one blog that shills for the industry -- DrugWonks run by PR agency Manning, Selvage and Lee's Peter Pitts -- is devoted to counteracting negative industry stories in the press.
Until recently, I didn't buy their arguments. I've seen as many stories in the press touting pharmaceutical products and practices as I have seen criticizing them (see, for example, "Am I Dreaming, or Is This [News Story] a Rozerem Ad?"). But the recent hiring by Brandweek of Peter Rost -- unabashedly a drug industry foe (he is, after all, a whistleblower and built a business on whistleblowing) -- to take over for Jim Edwards at BrandweekNRX blog has jaded my opinion of the media.
As I pointed out over at Pharma BlogosphereTM, "Rost as BrandweekNRX blogger makes perfect sense... if you intend to flush your blog down the drain as far as pharmaceutical industry readers are concerned -- except for their lawyers, that is." (See "It's Official. Rost Takes Over BrandweekNRX!")
I say this based upon two bits of research I have done:
- Pharma Blogosphere Survey: The First Ever Survey of Readers About Pharma Blog Credibility, Readability, Usefulness, and Bias (see Summary here).
- Pharma Marketing Blog Reader Survey (see a interactive Summary here)
The Pharma Blogosphere reader survey is more revealing as the following charts show.
There's a saying us Brooklynites have to live with all our lives, no matter where we end up calling home:
"You can take the girl [boy] out of Brooklyn, but you can't take Brooklyn out of the girl [boy]."
Which means, you can always recognize someone from Brooklyn by their accent and bias for their place of birth.
Applying this to Rost at BrandweekNRX, you could say that "You can take Rost out of Question Authority [where he is anti-industry], but you can't all of a sudden expect him to be an unbiased journalist."
IMHO, Brandweek should seriously consider the data I have presented above, because it signals that BrandweekNRX may lose some of its credibility and usefulness, especially among its most important audience: pharmaceutical executives.
Of course, you have to balance that against all the great publicity and perhaps greater readability that Rost will bring to BrandweekNRX.
The notoriety, however, will not last long. Perhaps that's why Rost hints his stint at BrandweekNRX may only be a temporary assignment (ie, "for a while"). Maybe it's destined to last only until Brandweek sees the numbers from its own reader research!